On Feb. 11, 2011, clinical trial patient recruitment and retention organization MMG will host a groundbreaking forum, “Todos Juntos por la Salud” or “All Together for Health,” which will address the state of Hispanic and Latino participation in medical research. Through this seminal initiative, MMG will partner with Hispanic and Latino healthcare community leaders to improve understanding of the research barriers faced by Hispanics and Latinos and identify strategies for overcoming them.
Although Hispanics and Latinos represent 16 percent of the US population, they constitute only 3 percent of the approximately 260,000 Americans who volunteer to participate in medical research each year. With the US Hispanic population expected to triple by 2050, steps need to be taken now to achieve greater Hispanic and Latino representation in medical research.
The forum will feature Hispanic and Latino community leaders and health industry stakeholders who will discuss the root causes behind the disparities in medical research participation, share ideas about what needs to occur to increase engagement, and strategize about how groups can collaborate to achieve these goals. Forum outcomes will be publicized to raise awareness, promote best practices, and build on the initiative’s momentum.
“We at MMG feel an urgency to address the disparity in clinical research access and participation among the US Hispanic and Latino populations,” said MMG CEO John Benbrook. “MMG is committed to applying our relationships and insights from our daily work to leading efforts that will get at the heart of these issues and drive tangible change."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.